27480504|t|Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema
27480504|a|Chronic hand eczema (CHE) is a common inflammatory skin disease that affects approximately 10% of the population. Systemic alitretinoin has been shown to be effective in patients with CHE who are refractory to topical corticosteroids. To analyse the impact of alitretinoin on the skin barrier genes and protein expression in the skin lesions of patients with CHE. Fifteen patients with CHE were treated with 30 mg daily of alitretinoin for up to 27 weeks. Disease severity was assessed using a clinical score. Skin biopsies from all the patients were evaluated before and after therapy for the expression of Ki-67, various skin barrier genes and thymic stromal lymphopoietin (TSLP) by real-time quantitative polymerase chain reaction and immunohistochemistry. After alitretinoin application, an improvement in the clinical severity of CHE was observed in the majority of patients. Analysis of skin biopsies before treatment showed a significant increase in Ki-67 - positive cells in the suprabasal layer and a dysregulated expression of various skin barrier genes, such as claudin 1, loricrin, filaggrin and cytokeratin 10, which were normalized after treatment. TSLP was significantly upregulated in patients with CHE and also normalized after alitretinoin treatment and negatively correlated with filaggrin. Our data indicate that the expression of barrier genes and proteins was normalized following treatment with alitretinoin in patients with CHE. The change in expression levels of these genes correlated with the clinical efficacy, suggesting that alitretinoin exhibits a disease - modifying activity. TSLP is upregulated in CHE and seems to counteract filaggrin expression in the skin.
27480504	19	31	alitretinoin	T103	UMLS:C0281666
27480504	32	41	treatment	T058	UMLS:C0087111
27480504	45	57	skin barrier	T038	UMLS:C2246986
27480504	58	62	gene	T038	UMLS:C0017262
27480504	67	85	protein expression	T038	UMLS:C1171362
27480504	103	122	chronic hand eczema	T038	UMLS:C1276092
27480504	123	142	Chronic hand eczema	T038	UMLS:C1276092
27480504	144	147	CHE	T038	UMLS:C1276092
27480504	161	186	inflammatory skin disease	T038	UMLS:C3875321
27480504	225	235	population	T098	UMLS:C1257890
27480504	246	258	alitretinoin	T103	UMLS:C0281666
27480504	307	310	CHE	T038	UMLS:C1276092
27480504	333	356	topical corticosteroids	T103	UMLS:C0304604
27480504	383	395	alitretinoin	T103	UMLS:C0281666
27480504	403	415	skin barrier	T038	UMLS:C2246986
27480504	416	421	genes	T017	UMLS:C0017337
27480504	426	444	protein expression	T038	UMLS:C1171362
27480504	452	464	skin lesions	T038	UMLS:C0037284
27480504	482	485	CHE	T038	UMLS:C1276092
27480504	509	512	CHE	T038	UMLS:C1276092
27480504	518	530	treated with	T058	UMLS:C0332293
27480504	546	558	alitretinoin	T103	UMLS:C0281666
27480504	633	646	Skin biopsies	T058	UMLS:C0150866
27480504	674	683	evaluated	T058	UMLS:C0220825
27480504	701	708	therapy	T058	UMLS:C0087111
27480504	717	727	expression	T038	UMLS:C1171362
27480504	731	736	Ki-67	T103	UMLS:C0208804
27480504	746	758	skin barrier	T038	UMLS:C2246986
27480504	759	764	genes	T017	UMLS:C0017337
27480504	769	797	thymic stromal lymphopoietin	T103	UMLS:C0762640
27480504	799	803	TSLP	T103	UMLS:C0762640
27480504	808	856	real-time quantitative polymerase chain reaction	T062	UMLS:C3179034
27480504	861	881	immunohistochemistry	T058	UMLS:C0021044
27480504	889	901	alitretinoin	T103	UMLS:C0281666
27480504	958	961	CHE	T038	UMLS:C1276092
27480504	1004	1012	Analysis	T062	UMLS:C0936012
27480504	1016	1029	skin biopsies	T058	UMLS:C0150866
27480504	1037	1046	treatment	T058	UMLS:C0087111
27480504	1080	1085	Ki-67	T017	UMLS:C1334508
27480504	1088	1096	positive	T033	UMLS:C1514241
27480504	1097	1102	cells	T017	UMLS:C0007634
27480504	1110	1126	suprabasal layer	T017	UMLS:C0243092
27480504	1133	1156	dysregulated expression	T038	UMLS:C0017263
27480504	1168	1180	skin barrier	T038	UMLS:C2246986
27480504	1181	1186	genes	T017	UMLS:C0017337
27480504	1196	1205	claudin 1	T017	UMLS:C1413460
27480504	1207	1215	loricrin	T017	UMLS:C1416897
27480504	1217	1226	filaggrin	T017	UMLS:C1414633
27480504	1231	1245	cytokeratin 10	T017	UMLS:C1416714
27480504	1258	1268	normalized	T062	UMLS:C1882115
27480504	1275	1284	treatment	T058	UMLS:C0087111
27480504	1286	1290	TSLP	T103	UMLS:C0762640
27480504	1309	1320	upregulated	T038	UMLS:C0041904
27480504	1338	1341	CHE	T038	UMLS:C1276092
27480504	1351	1361	normalized	T062	UMLS:C1882115
27480504	1368	1380	alitretinoin	T103	UMLS:C0281666
27480504	1381	1390	treatment	T058	UMLS:C0087111
27480504	1395	1405	negatively	T033	UMLS:C1513916
27480504	1422	1431	filaggrin	T103	UMLS:C0117738
27480504	1482	1487	genes	T017	UMLS:C0017337
27480504	1492	1500	proteins	T103	UMLS:C0033684
27480504	1505	1515	normalized	T062	UMLS:C1882115
27480504	1526	1535	treatment	T058	UMLS:C0087111
27480504	1541	1553	alitretinoin	T103	UMLS:C0281666
27480504	1571	1574	CHE	T038	UMLS:C1276092
27480504	1590	1600	expression	T038	UMLS:C0017262
27480504	1617	1622	genes	T017	UMLS:C0017337
27480504	1678	1690	alitretinoin	T103	UMLS:C0281666
27480504	1702	1709	disease	T038	UMLS:C0012634
27480504	1732	1736	TSLP	T103	UMLS:C0762640
27480504	1740	1751	upregulated	T038	UMLS:C0041904
27480504	1755	1758	CHE	T038	UMLS:C1276092
27480504	1783	1792	filaggrin	T103	UMLS:C0117738
27480504	1793	1803	expression	T038	UMLS:C1171362
27480504	1811	1815	skin	T022	UMLS:C1123023